Introduction/Background Neoadjuvant chemotherapy followed by interval debulking surgery is used in the treatment of advanced ovarian cancer. However, no tool can safely predict if complete cytoreduction after 3–4 cycles can be achieved. KELIM is a modeled kinetic parameter based on CA-125 values measured during the first 100 days of neoadjuvant chemotherapy. This study aims to investigate if KELIM score can be a tool in the identification of patients that can achieve a complete interval debulking surgery (IDS).

Methodology We retrospectively analyzed the records of patients with advanced ovarian cancer that were treated in the 1st Department of Obstetrics – Gynecology Clinic from 2012 – 2022 with neoadjuvant chemotherapy followed by IDS. Patient characteristics, oncological and follow-up information were collected. KELIM score was measured with the online tool, biomarker-kinetics.org. The primary outcome was the association of KELIM score and residual disease.

Results Out of 128 patients, 83 had the available data to be included in the final analysis. Patients were categorized into two groups: Group A (51 patients) favorable (≥1) and Group B (32 patients) unfavorable (<1) KELIM scores. There was no statistically significant difference in age, BMI, comorbidities, postoperative complications, and hospital stay between the two groups. However, statistically significant correlation between KELIM and residual disease (p<0.05) exists, showing that patients with a favorable KELIM score can achieve a complete IDS. There was only one case with favorable KELIM that led to an optimal cytoreduction, because of milliary disease in the small bowel. Concerning survival rates, there was a statistically significant difference in overall survival (p=0.0176), but no difference was observed in progression-free survival (p=0.143).

Conclusion KELIM seems to be a tool to safely triage patients after neoadjuvant chemotherapy and decide who can undergo IDS, while patients with unfavorable KELIM score can undergo diagnostic laparoscopy, to assess tumor resectability.

Disclosures No disclosures